Allergic patients during the COVID-19 pandemic-Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey.
COVID‐19
allergen immunotherapy
allergy
biologics
survey
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
25
11
2021
accepted:
18
12
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has affected health care systems unexpectedly. However, data focusing on practical considerations experienced by health care professionals (HCPs) providing care to allergic patients is scarce. Under the framework of the European Academy of Allergy and Clinical Immunology (EAACI), a panel of experts in the field of immunotherapy developed a 42-question online survey, to evaluate real-life consequences of the COVID-19 pandemic in allergy practice. The respondents in the survey were 618. About 80% of HCPs indicated being significantly affected in their allergy practice. A face-to-face visit reduction was reported by 93% of HCPs and about a quarter completely interrupted diagnostic challenges. Patients with severe uncontrolled asthma (59%) and anaphylaxis (47%) were prioritized for in-person care. About 81% maintained an unaltered prescription of inhaled corticosteroids (ICS) in asthmatics. About 90% did not modify intranasal corticosteroids (INCS) in patients with allergic rhinitis. Nearly half of respondents kept biological prescriptions unmodified for asthma. About 50% of respondents kept their allergen immunotherapy (AIT) prescription patterns unchanged for respiratory allergies; 60% for insect venom allergies. Oral immunotherapy (OIT) for food allergies was initiated by 27%. About 20% kept carrying out up-dosing without modifications and 14% changed to more prolonged intervals. Telemedicine practice was increased. HCPs providing care to allergic patients were affected during the pandemic in diagnostic, management, and therapeutic approaches, including AIT for respiratory, insect-venom, and food allergies. Most HCPs maintained controller treatments for both asthma, and allergic rhinitis consistent with international recommendations, as well as biological agents in asthma. Remote tools are valuable in delivering allergy care.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic has affected health care systems unexpectedly. However, data focusing on practical considerations experienced by health care professionals (HCPs) providing care to allergic patients is scarce.
METHODS
METHODS
Under the framework of the European Academy of Allergy and Clinical Immunology (EAACI), a panel of experts in the field of immunotherapy developed a 42-question online survey, to evaluate real-life consequences of the COVID-19 pandemic in allergy practice.
RESULTS
RESULTS
The respondents in the survey were 618. About 80% of HCPs indicated being significantly affected in their allergy practice. A face-to-face visit reduction was reported by 93% of HCPs and about a quarter completely interrupted diagnostic challenges. Patients with severe uncontrolled asthma (59%) and anaphylaxis (47%) were prioritized for in-person care. About 81% maintained an unaltered prescription of inhaled corticosteroids (ICS) in asthmatics. About 90% did not modify intranasal corticosteroids (INCS) in patients with allergic rhinitis. Nearly half of respondents kept biological prescriptions unmodified for asthma. About 50% of respondents kept their allergen immunotherapy (AIT) prescription patterns unchanged for respiratory allergies; 60% for insect venom allergies. Oral immunotherapy (OIT) for food allergies was initiated by 27%. About 20% kept carrying out up-dosing without modifications and 14% changed to more prolonged intervals. Telemedicine practice was increased.
CONCLUSIONS
CONCLUSIONS
HCPs providing care to allergic patients were affected during the pandemic in diagnostic, management, and therapeutic approaches, including AIT for respiratory, insect-venom, and food allergies. Most HCPs maintained controller treatments for both asthma, and allergic rhinitis consistent with international recommendations, as well as biological agents in asthma. Remote tools are valuable in delivering allergy care.
Identifiants
pubmed: 35070270
doi: 10.1002/clt2.12097
pii: CLT212097
pmc: PMC8762981
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12097Informations de copyright
© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Int Arch Allergy Immunol. 2021;182(1):49-52
pubmed: 33059353
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5
pubmed: 32224232
Allergy Asthma Immunol Res. 2020 Sep;12(5):783-791
pubmed: 32638559
Allergy. 2021 Jun;76(6):1765-1775
pubmed: 33608919
Allergy. 2020 Oct;75(10):2503-2541
pubmed: 32535955
J Allergy Clin Immunol Pract. 2019 Jan;7(1):199-216.e11
pubmed: 30055283
J Allergy Clin Immunol Pract. 2020 Nov - Dec;8(10):3671-3672
pubmed: 32890757
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Asian Pac J Allergy Immunol. 2021 Apr 18;:
pubmed: 33865299
Allergy. 2020 Nov;75(11):2764-2774
pubmed: 32500526
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2461-2473.e3
pubmed: 32603900
Clin Microbiol Infect. 2021 Aug;27(8):1158-1166
pubmed: 33915287
Allergy. 2021 Mar;76(3):689-697
pubmed: 32588922
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):300-1
pubmed: 25609330
Allergy. 2021 Nov;76(11):3504-3516
pubmed: 33655519
Ann Allergy Asthma Immunol. 2020 Oct;125(4):478-479
pubmed: 32585178
Aging Male. 2020 Dec;23(5):1416-1424
pubmed: 32508193
Allergy. 2021 Feb;76(2):510-532
pubmed: 32524611
Clin Mol Allergy. 2020 Oct 1;18:18
pubmed: 33020697
Pediatr Allergy Immunol. 2020 Jul;31(5):442-448
pubmed: 32319129
Ital J Pediatr. 2020 Jun 16;46(1):84
pubmed: 32546234
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2592-2599.e3
pubmed: 32561497
J Allergy Clin Immunol. 2020 Aug;146(2):307-314.e4
pubmed: 32554082
Allergy. 2020 Jul;75(7):1699-1709
pubmed: 32196678
J Allergy Clin Immunol Pract. 2019 Mar;7(3):1017-1021
pubmed: 30385405
J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2033-2040
pubmed: 29751152
Allergo J Int. 2021 Feb 22;:1-11
pubmed: 33758744
Allergy. 2021 Mar;76(3):648-676
pubmed: 32531110
Allergy. 2020 Jul;75(7):1546-1554
pubmed: 32329930
J Allergy Clin Immunol Pract. 2021 Feb;9(2):709-722.e2
pubmed: 33271350
Laryngorhinootologie. 2020 Oct;99(10):676-679
pubmed: 32823368
Biomedicines. 2021 Mar 30;9(4):
pubmed: 33808197
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2771-2773
pubmed: 32470444
Viruses. 2020 Mar 27;12(4):
pubmed: 32230900
Eur Respir J. 2020 May 7;55(5):
pubmed: 32341100
Front Pediatr. 2020 Nov 23;8:565039
pubmed: 33330268
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
Allergo J Int. 2020;29(8):257-261
pubmed: 33312843
Pediatr Allergy Immunol. 2020 May;31 Suppl 25:1-101
pubmed: 32436290
Allergol Select. 2021 Apr 1;5:140-147
pubmed: 33842829
J Asthma. 2021 Apr 23;:1-7
pubmed: 33863266
Allergy. 2021 Mar;76(3):622-625
pubmed: 32589296
PLoS One. 2021 Mar 31;16(3):e0243291
pubmed: 33788846
Allergy. 2020 Oct;75(10):2440-2444
pubmed: 32233040
World Allergy Organ J. 2021 Feb;14(2):100515
pubmed: 33552380